
Amplio Pharma has reported phase 1b results for NovoBioJect, an investigational combination of low-dose methotrexate (MTX) and novobiocin being developed …
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership

